Nor do you. It leads to question though a few things. Time line for resubmitting, cost (dilution) of process and if someone else beats them to it? Right now you have a company running in plan B mode generics with a large black eye from the FDA. Explain to me how this is not just another typical OTC?
News 
Market Data 
Discover 
AI
